UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Annals of oncology, 2014-02, Vol.25 (2), p.423-428

2014

Volltextzugriff (PDF)

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Annals of oncology, 2014-02, Vol.25 (2), p.415-422

2014

Volltextzugriff (PDF)

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

Annals of oncology, 2013-01, Vol.24 (1), p.59-66

2013

Volltextzugriff (PDF)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Annals of oncology, 2019-07, Vol.30 (7), p.1121-1126

2019

Volltextzugriff (PDF)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Annals of oncology, 2019-05, Vol.30 (5), p.839-844

2019

Volltextzugriff (PDF)

Optimizing Treatment for Patients With Anaplastic Lymphoma Kinase‐Positive Lung Cancer

Clinical pharmacology and therapeutics, 2017-05, Vol.101 (5), p.625-633

2017

Volltextzugriff (PDF)

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Annals of oncology, 2020-05, Vol.31 (5), p.599-608

2020

Volltextzugriff (PDF)

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Annals of oncology, 2018-10, Vol.29 (10), p.2085-2091

2018

Volltextzugriff (PDF)

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

Annals of oncology, 2019-04, Vol.30 (4), p.597-603

2019

Volltextzugriff (PDF)

Investigation of patterns of nodal metastases in BRAF mutant lung cancer

Lung cancer (Amsterdam, Netherlands), 2017-06, Vol.108, p.62-65

2017

Volltextzugriff (PDF)

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Annals of oncology, 2016-07, Vol.27 (7), p.1286-1291

2016

Volltextzugriff (PDF)

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers

Annals of oncology, 2017-02, Vol.28 (2), p.278-284

2017

Volltextzugriff (PDF)

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001

Annals of oncology, 2019-04, Vol.30, p.ii48-ii49

2019

Volltextzugriff (PDF)

Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)

Annals of oncology, 2018-10, Vol.29, p.viii503-viii503

2018

Volltextzugriff (PDF)

Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations

Annals of oncology, 2018-10, Vol.29, p.viii495-viii495

2018

Volltextzugriff (PDF)

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

ESMO open, 2023-04, Vol.8 (2), p.101160-101160, Article 101160

2023

Volltextzugriff (PDF)

COVID-19 in patients with lung cancer

Annals of oncology, 2020-10, Vol.31 (10), p.1386-1396

2020

Volltextzugriff (PDF)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Annals of oncology, 2019-08, Vol.30 (8), p.1311-1320

2019

Volltextzugriff (PDF)

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Cancer, 2015-09, Vol.121 (18), p.3212-3220

2015

Volltextzugriff (PDF)

KRAS mutations in non-small cell lung cancer

Proceedings of the American Thoracic Society, 2009-04, Vol.6 (2), p.201-205

2009

Volltextzugriff (PDF)

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer

Nature medicine, 2017-08, Vol.23 (8)

2017

Volltextzugriff (PDF)

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

Journal of thoracic oncology, 2014-11, Vol.9 (11), p.1669-1674

2014

Volltextzugriff (PDF)

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

European journal of cancer (1990), 2020-10, Vol.138, p.S1-S2

2020

Volltextzugriff (PDF)

Negative Regulation of T Cell Activation by Placental Protein 14 Is Mediated by the Tyrosine Phosphatase Receptor CD45

The Journal of biological chemistry, 2003-04, Vol.278 (16), p.14059-14065

2003

Volltextzugriff (PDF)

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

PLoS medicine, 2005-03, Vol.2 (3), p.e73-e73

2005

Volltextzugriff (PDF)

1 – 25 von 361

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(345)
Mit Volltextzugriff
(324)

Publikationsform

Sprache

Englisch
(360)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(166)
Humans
(159)
Life Sciences & Biomedicine
(158)
Oncology
(134)
Female
(100)
Male
(97)
Middle Aged
(89)
Aged
(84)
Lung Neoplasms - Genetics
(84)
Lung Neoplasms - Drug Therapy
(81)
Mutation
(72)
Adult
(66)
Aged, 80 And Over
(57)
Lung Neoplasms - Pathology
(54)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(46)
Biological And Medical Sciences
(45)
Medical Sciences
(43)
Carcinoma, Non-Small-Cell Lung - Genetics
(39)
Adenocarcinoma - Genetics
(38)
Lung Cancer
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Optimizing Treatment for Patients With Anaplastic Lymphoma Kinase‐Positive Lung Cancer

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

Investigation of patterns of nodal metastases in BRAF mutant lung cancer

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001

Efficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)

Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

COVID-19 in patients with lung cancer

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

KRAS mutations in non-small cell lung cancer

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

Negative Regulation of T Cell Activation by Placental Protein 14 Is Mediated by the Tyrosine Phosphatase Receptor CD45

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Suchergebnisse filtern